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Skeletal muscle
Sodium tungstateThe balance between the rates of protein synthesis and degradation in muscle is regulated by PI3K/
Akt signaling. Here we addressed the effect of ERK activation by sodium tungstate on protein
turnover in rat L6 myotubes. Phosphorylation of ERK by this compound increased protein synthesis
by activating MTOR and prevented dexamethasone-induced protein degradation by blocking
FoxO3a activity, but it did not alter Akt phosphorylation. Thus, activation of ERK by tungstate
improves protein turnover in dexamethasone-treated cells. On the basis of our results, we propose
that tungstate be considered an alternative to IGF-I and its analogs in the prevention of skeletal
muscle atrophy.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction phosphorylation of a repressor of MTOR, the tuberous sclerosisThe maintenance of skeletal muscle mass is crucial for long-
term health and quality of life. Skeletal muscle mass is generally
determined by the dynamic balance between protein synthesis
and protein degradation [1]. These two processes are closely con-
nected and regulated in such way that when protein synthesis is
induced, degradation is suppressed and vice versa.
The mechanistic target of rapamycin (MTOR) plays a central
role in regulating the rate of protein synthesis in skeletal muscle.
Speciﬁcally, MTOR controls this rate via phosphorylation of its
downstream effector, the ribosomal S6 kinase 1 (S6K1) [1–4]. Acti-
vation of the phosphoinositide 3-kinase (PI3K)/Akt and extracellu-
lar signal-regulated kinase (ERK) signaling pathways results in thecomplex (TSC), consisting of TSC1 and TSC2 [3]. The phosphoryla-
tion of TSC2 at Thr1462 and Ser939 by Akt [5] or at Ser664 by ERK
[6] activates ﬁrst MTOR and then S6K1, a key translation initiation
regulator [7].
Protein degradation in skeletal muscle is essentially mediated
by the activity of two conserved pathways: the ubiquitin-proteaso-
mal and the autophagic/lysosomal pathways [8]. Responsible for
the turnover of most soluble and myoﬁbrillar muscle proteins,
the activity of the former is markedly enhanced in atrophying mus-
cle as a result of increased expression of ubiquitin and ubiquitin
ligases, such as ATROGEN1 and MuRF1 [8,9]. Autophagy also plays
a key role in protein degradation in skeletal muscle and involves an
ordered stimulation of a battery of genes, such as LC3, p62 and
Bnip3 [8].
The two degradation pathways are controlled by the Forkhead
box O3 (FoxO3) transcription factor. FoxO3 is normally phosphor-
ylated and inactivated by Akt, but in the absence of Akt repression
it translocates to the nucleus and induces the expression of
MuRF-1 and ATROGEN1, as well as many genes related to
autophagy [9–11].
Several potential therapeutic targets have been identiﬁed for
muscular atrophy, although an effective drug to counteract muscle
wasting is not yet available. The most promising targets belong to
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example, the IGF1/Akt axis controls both protein synthesis and
degradation [3,11,12], and analogs of IGF1 have been used to ame-
liorate or impede muscle loss.
Here we analyzed changes in the phosphorylation and expres-
sion of key proteins involved in the regulation of protein synthesis
and protein degradation in response to sodium tungstate (W) in
skeletal L6 muscle cells. Pre-treatment with tungstate, a compound
that activates the ERK but not the PI3K/Akt signaling pathway
[13–17], not only increased protein synthesis through the activa-
tion of MTOR but also restored the activity, sub-cellular location
and expression of proteins involved in proteolysis to basal control
levels. This was achieved by a FoxO3a-dependent mechanism.2. Materials and methods
2.1. Materials
Sodium tungstate, dexamethasone (DEX), rapamycin, wortman-
nin, PD98059 and baﬁlomycinA1 were obtained from Sigma (St.
Louis, MO, USA). Tissue culture media, fetal bovine serum (FBS)
and supplements were from Sigma. ERK1/2 and phospho-ERK1/2
E10 (Thr202/Tyr204), protein kinase B (PKB/Akt) and phospho-
PKB/Akt (Ser473), MTOR and phospho-MTOR (Ser 2448), S6K1
and phospho-S6K1 (Thr389), Phospho-4E-BP1 (Ser 65) and eIF4E-
binding protein 1 (4E-BP1) antibodies were from Cell Signaling
Technology (Beverly, MA, USA). Antibodies against Tuberin
(TSC2), FKHRL1 (FoxO3a), phospho-FKHRL1 (FoxO3a) (Thr32),
MuRF1 and SQSTM1 (p62) were supplied by Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Phospho-tuberin (P-TSC2) (Ser664) anti-
body was from Abcam (Cambridge, UK). FBXO32 (Atrogen1)
antibody was purchased from Acris Antibodies GmbH (Herford,
Germany). Antibodies against eukaryotic initiation factor (eIF4E)
and phospho-eIF4E (Ser209) were obtained from Signalway Anti-
body LLC (SAB) (College Park, MD, USA). Histone H3 antibody
was provided by Epitomics (Burlingame, California). LC3 clone
5F10 antibody was from Nanotools (München, Germany). HRP-
conjugated secondary antibodies were obtained from Bio-Rad
(Madrid, Spain). Plasmid pGFP-LC3 was kindly provided by Profes-
sor T. Yoshimori (Department of Genetics, Osaka University), Add-
gene plasmid #21073.
2.2. Cell culture
The L6.C11 rat skeletal muscle myoblast line (ECACC No.
92102119) was grown in DMEM containing 10% (v/v) FBS,
2 mmol/l glutamine plus 100 units/ml penicillin and 0.1 mg/ml
streptomycin and maintained at subconﬂuent densities. Cells were
differentiated to myotubes by exchanging the growth medium for
a differentiation medium comprising DMEM containing 2% (v/v)
FCS for 5 days (>50% fusion into multinucleated myotubes).
2.3. Determination of protein synthesis
L6 cells were plated in 48-well tissue culture plates, differenti-
ated for 5 days, and then deprived of FBS for 16–18 h. Cells were
treated with effectors for 2 h in normal culture media (10% FBS)
and 0.8 mmol/l Tyr. They were then spiked with 1 lCi/ml of
L-(ring-3,5-3H)-Tyr (Perkin Elmer, Waltham, MA, USA) and incu-
bated for 1 h. The reaction was stopped by placing the plates on
ice. All wells were thoroughly washed twice with ice-cold PBS-
media containing 2 mM non-radioactive Tyr, and the cells were
then lysed in 0.1 mM NaOH/0.1% sodium deoxycholate. The cellu-
lar proteins were precipitated by adding cold 20% trichloroacetic
acid (TCA) (Sigma). This mixture was then incubated at 4 C for15 min. After centrifugation (16000xg for 10 min), the pellet was
washed once with cold 10% TCA, and then the precipitated proteins
were dissolved in 0.1 ml of 1 M NaOH. An aliquot (5 ll) of the
NaOH-solubilized material was used for total protein quantitation.
The remaining dissolved proteins were neutralized with 1 M HCl
and mixed with ReadySafe scintillation ﬂuid (Beckman Coulter,
Brea CA). Radiolabel was determined with a scintillation counter
(Beckman Coulter). Data were computed as dpm/lg of proteins.
2.4. Protein degradation
Myotubes (5 days in differentiation media) were labeled with
1 lCi/ml of L-(ring-3,5-3H)-Tyr for 48 h in DMEM plus 10% FBS
in the presence or absence of 50 nM insulin or a range of concen-
trations of W. Cells were rinsed once in PBS-Tyr and then placed
in DMEM supplemented with 10% FBS and 2 mM L-Tyr for 2 h to
allow the degradation of short-lived-proteins. They were then
rinsed twice in PBS-Tyr, and fresh degradation medium was added.
Cells were incubated for an additional 24 h in the presence or
absence of 5 lM dexamethasone. Degradation rates were deter-
mined as previously described [18].
2.5. Quantitation of proteins involved in protein turnover
To study the phosphorylation status of the proteins involved in
signaling events, L6 myotubes were deprived of FBS for 16–18 h
and then incubated with 50 nM insulin or increasing concentra-
tions of W for 30 min in serum free-medium. Plates were ﬂash fro-
zen in liquid nitrogen and processed as described previously [15].
To study the expression of proteins associated with protein deg-
radation, cells were pre-incubated in DMEM with 10% FBS with
0.5 mM tungstate or 50 nM insulin for 48 h and then incubated
for 24 h in the absence or presence of 5 lM DEX. After the treat-
ments, they were lysed with RIPA buffer supplemented with phos-
phatase and protease inhibitors, 10 mM sodium ﬂuoride, 10 mM
sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM EGTA,
20 nM okadaic acid, 10 lg/ml aprotinin, 10 lg/ml leupeptin, and
10 lg/ml pepstatin.
The protein concentration of the lysates was measured using
the bicinchoninic acid method [19]. Proteins were separated by
SDS–PAGE by loading 30 lg of total protein per lane and were then
transferred to nitrocellulose membranes (Schleicher and Schuell,
Dassel, Germany) and immunoblotted with selected antibodies;
the immunoblots were developed using an enhanced chemilumi-
nescence detection system.
2.6. FoxO and ubiquitin luciferase assays
FoxO-dependent transcriptional activity was assayed using a
Cignal FoxO-luciferase reporter kit (SABiosciences, Valencia, CA)
containing a mixture of an inducible FoxO-responsive ﬁreﬂy lucif-
erase construct and a constitutively expressing Renilla luciferase
construct. To evaluate the ubiquitin C (UbC) promoter activity, a
417-bp fragment ﬂanking the transcription start point (340 to
+63 bp) was ampliﬁed from rat genomic DNA by PCR and cloned
in the pGL3-basic plasmid (Promega, Madison, WI, USA). This frag-
ment is similar to that characterized for the rat UbC promoter [20].
The construct was veriﬁed by automated DNA sequencing.
Cells were transfected with either the Cignal FoxO mixture or
PGL3-UbC plus the pRLTK Renilla luciferase control plasmid
(95:5) using LipofectAMINE 2000, as described previously [14].
Fireﬂy and Renilla luciferase activity was measured using the Dual
Luciferase Assay System (Promega), following a standard protocol
using a Sirius L luminometer (Berthold Technologies, Bad Wildbad,
Germany). Data were expressed as relative changes in luciferase
activity and normalized to 100%.
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Nuclear extracts from L6 cells were prepared as described [21].
Protein concentration was measured in nuclear extracts using the
bicinchoninic acid method. Aliquots of the extracts (30 lg) were
resolved by SDS–PAGE and analyzed by immunoblotting using
anti-FoxO3a or anti-Histone3 antibodies.C DEX W W + DEX
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A 2.8. RNA puriﬁcation and retrotranscription
Total RNA was isolated from L6 myotubes using the GeneJet
RNA Puriﬁcation Kit (Thermo Scientiﬁc). The amount of total RNA
was measured using a NanoVue Plus Spectrophotometer (GE
Healthcare Life Sciences) and the quality was veriﬁed by 1% aga-
rose gel electrophoresis. 1 lg of total RNA from each sample was
reverse-transcribed using Maxima First Strand cDNA Synthesis
Kit for RT-qPCR (Thermo Scientiﬁc).
2.9. Quantitative real-time PCR (qPCR)
The qPCR was performed using speciﬁc primers on a MiniOpticon
Real-Time PCRSystem (Bio-Rad) with Bio-Rad CFX Manager 3.1 soft-
ware and ﬂuorescence signal detection (SYBRGreen) after each ampli-
ﬁcation cycle. Sequences of the primers were for b-actin, Forward
50-AAGACCTCTATGCCAACAC-30 and Reverse 50-TGATCTTCATGGTGC-
TAGG-30; murf (Trim63), Forward 50-GTTTACTGAAGAGGAGGAGG-30
and Reverse 50-AGAAGACACACTTCCCTATG-30; Atrogen-1 (Fbxo32),
Forward 50-TACAACTGAACATCATGCAG-30 and Reverse 50-
GTACATCTTCTTCCAATCCAG-30 and Bnip3, Forward 50-CTACTCTCAG-
CATGAGAAAC-30 and Reverse 50-TCCAATGTAGATCCCCAATC-30. First
strand cDNA was used as template in 10 ll reactions including
5 ll of 2 iTaq Universal SYBR Green supermix and 500 nM of
each primer. Negative controls (with no DNA template) for each pri-
mer set were included in each run. qPCR cycling was performed at
95 C (2 min), followed by 40 cycles at 95 C (15 s), 57 C (30 s), and
ﬁnally amelt curve program (60–95 Cwith a heating rate of 0.1 C/
s and a continuous ﬂuorescence measurement). Measurements of
gene expression with regard to each RNA extraction were obtained
in triplicate. Relative expression of mRNA was calculated using the
2-ACt method with b-actin as an internal reference gene.
2.10. Autophagy assay
pGFP-LC3-transfected myotubes were used to demonstrate the
formation of autophagosomes. L6 cells were transfected with
pGFP-LC3 using LipofecAMINE 2000 and then differentiated to
myotubes. To determine LC3 localization, the cells were observed
under a ﬂuorescence microscope. Quantiﬁcation of positive
puncta/cell of at least 4 ﬁelds per treatment is represented.
2.11. Statistical analysis
Results are expressed as mean ± S.E.M. Statistical analysis was
performed by one-way ANOVA followed by Tukey’s test as appro-
priate. P < 0.05 was considered statistically signiﬁcant.Fig. 1. Effects of sodium tungstate on protein turnover in L6 myotubes. (A) Cells
were incubated for 2 h in DMEM containing 10% FBS with 0.1–0.5 mMW or 50 nM
insulin (I). (B) Cells were pre-incubated for 2 h in DMEM containing 10% FBS with
0.5 mMW and then incubated with 5 lM DEX in the presence or absence of W for
1 h. (C) Cells were pre-incubated for 48 h in DMEM containing 10% FBS with 0.1–
0.5 mMW or 50 nM insulin and then incubated for 24 h with 5 lM DEX in the
presence or absence of effectors. Protein synthesis (A and B) and protein
degradation (C) was determined as described in the Section 2. Data is expressed
as dpm/lg of proteins. Results are as means ± S.E.M. of eight independent
experiments.⁄P < 0.05 compared with untreated cells (C).3. Results
We addressed the effect of ERK activation by tungstate on
protein turnover in differentiated L6 myotubes. To this end, we
assayed the rates of protein synthesis and degradation and
dissected the inﬂuence of ERK activation on the molecular
mechanisms that participate in these two processes.3.1. Effects of sodium tungstate on protein turnover
W (0.1–0.5 mM) had a signiﬁcant positive effect on protein syn-
thesis (Fig. 1A). The effect of 0.1 mMW was similar to that of
50 nM insulin under similar conditions.
Next, we tested whether W counteracts the effects of DEX on
protein turnover. Incubation of L6 myotubes with 5 lM DEX pro-
duced a decrease in protein synthesis (Fig. 1B) and an increase in
protein degradation (Fig. 1C). The addition of W to cells 48 h before
DEX increased protein synthesis to control values (Fig. 1B) and
decreased DEX-induced protein degradation in a dose-dependent
manner.
Since MTOR is a key element in the regulation of protein syn-
thesis, we studied the effects of W on the phosphorylation of this
protein (Fig. 2A). W induced a dose-dependent increase in MTOR
phosphorylation, which paralleled the effects of the compound
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Fig. 2. Sodium tungstate increased MTOR signaling in L6 myotubes. Myotubes were deprived of FBS for 16–18 h. (A) They were treated with 0.1–0.5 mMW or 50 nM insulin
in the same medium for 30 min. Cells were lysed, and total protein was immunoblotted with speciﬁc MTOR phospho- and total-antibodies. A representative blot is shown
beneath the graph (n = 4). (B) Cells were then incubated in the same medium containing 0.5 mMW in the absence or presence of 25 nM rapamycin for 2 h. Rapamycin was
added 30 min prior to W and maintained during the experiment. Protein synthesis was assayed as above (n = 6). (C–E) Cells were treated as in A. Cells were lysed, and total
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ciﬁc MTOR inhibitor) blocked the effects of W (Fig. 2B), thus con-
ﬁrming the involvement of MTOR in the mechanism of action of
W on protein synthesis.
We subsequently focused on the effects of W and insulin on the
phosphorylation state of key kinases downstream of MTOR that
are involved in the regulation of protein synthesis. W increased
the phosphorylation of S6K1, 4E-BP1 (eIF4E-binding protein 1) and
eukaryotic initiation factor (eIF4E) in a dose-dependent way
(Fig. 4C–E). The incubation of cells with insulin led to higher phos-
phorylation levels of the kinases than when incubated with
tungstate.
3.2. Signaling upstream of MTOR modulated by sodium tungstate
PI3K/Akt and MEK/ERK signaling are the two main pathways
that regulate MTOR activity. In a previous study [15] we showed
that W does not induce the phosphorylation of Akt/PKB in L6 myo-
tubes. Here we conﬁrmed this observation (Fig. 3A). As described
previously, W increased ERK1/2 phosphorylation in a dose-depen-
dent manner (Fig. 3B). As expected, insulin enhanced the phos-
phorylation of Akt/PKB and ERK1/2.
Next, cells were pre-incubated with speciﬁc inhibitors of PKB/
Akt phosphorylation (wortmannin, 100 nM) or ERK1/2 activation
(PD98059, 20 lM), and protein synthesis was then assayed in the
presence or absence of 0.5 mM tungstate. TheW-mediated increase
in protein synthesis was blocked by pre-incubation with PD98059,
but not with wortmannin, thereby conﬁrming that only ERK1/2
activation is involved in the tungstate-mediated effects on protein
synthesis (Fig. 3C). Furthermore, TSC2 (S664) phosphorylation is a
hallmark of ERK-mediated MTOR activation [6]. In this regard, anincrease in the phosphorylation of TSC2 at S664 in cells incubated
either with 0.5 mMW or 50 nM insulin was observed (Fig. 3D).
3.3. ERK activation by tungstate is concomitant with a decrease in
FoxO3a activity
In muscle, DEX-induced protein degradation is mediated by the
activation of the ubiquitin–proteasome pathway and also by the
induction of the lysosomal pathway of protein degradation. A key
element controlling both pathways is the transcriptional regulator
FoxO3A [8–10,22].
In order to measure FoxO-dependent transcriptional activity, L6
cells were transfected with an inducible FoxO-responsive ﬁreﬂy
luciferase construct, differentiated to myotubes, and then incu-
bated with 0.5 mMW or 50 nM insulin. After 48 h, 5 lM DEX was
added, and the cells were further incubated in its presence or
absence for 24 h. While DEX increased luciferase activity, pre-incu-
bation with W or insulin blocked the increase in FoxO-dependent
transcriptional activity caused by DEX. Neither W nor insulin alone
modiﬁed the FoxO-dependent luciferase activity (Fig. 4A).
When phosphorylated, FoxO3a remains in the cytosol as an inac-
tive transcription factor [9,11]. Both W and insulin increased the
phosphorylation of this protein in the cytosol related to DEX treated
cells and also counteracted the DEX-induced decrease in its phos-
phorylation state (Fig. 4B). Moreover, nuclear extracts from DEX-
treated cells showed an increase in FoxO3a, while no changes were
observed in W- or insulin-treated cells with respect to the controls
(Fig. 4C). Again, pre-incubation with both agents neutralized the
effects of DEX.
Next, we studied the inﬂuence of DEX and W on the regulation
of the ubiquitin–proteasome pathway. For this purpose, we ana-
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2250 R. Salto et al. / FEBS Letters 588 (2014) 2246–2254lyzed the effects of W and insulin on the regulation of the ubiquitin
promoter activity and the expression and mRNA levels of the main
ubiquitin ligases MuRF1 and ATROGEN1 (Fig. 5). W counteracted
the increase caused by DEX treatment in ubiquitin promoter-
dependent transcription (Fig. 5A), expression (Fig. 5B and D), and
mRNA levels (Fig. 5C and E) of the two ubiquitin ligases. Differ-
ences between protein (Fig. 5B) and mRNA (Fig. 5C) levels of
MuRF1 in the insulin plus DEX-treated cells suggest that MuRF1
protein expression was controlled post-transcriptionally.LC3 which is involved in autophagosome biogenesis [8,23] is
one of the genes whose expression is increased by FoxO3a. To
study whether W is also involved in lysosomal proteolysis, we per-
formed Western blots for LC3, which is cleaved and conjugated to
phosphatylethanolamine during the formation of autophagosomes,
thus generating a faster migrating form, namely LC3-II [24]. The
intensity of the LC3-II bands shown was calculated relative to the
actin band from the same membrane. Incubation with DEX was
associated with an accumulation of LC3-II, but this effect was
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blocked lysosomal degradation of autophagosomes by incubation
with baﬁlomycinA1 [23], a signiﬁcant increase in the expression
of LC3-II was observed in the DEX-treated cells (Fig. 6B). Both W
and insulin counteracted this increase induced by DEX in LC3II lev-
els. To conﬁrm the preventive effects of W on autophagy, we mon-
itored autophagosome formation by transfecting L6 cells with a
GFP-LC3 plasmid [9,10] (Supplemental Fig. 1). Experiments were
carried out in the presence of baﬁlomycin A1. DEX treatment
induced an increase in the formation of GFP-positive puncta. How-
ever, cells pre-incubated with W showed a decrease in GFP-tagged
autophagosomes.The expression of p62 (also known as SQSTM1/sequestome 1)
was also measured (Fig. 6C). P62 is incorporated into autophagic
vacuoles through interaction with LC3 [23,25]. While incubation
with DEX decreased the expression of p62, pre-incubation with
W or insulin blocked the effects of DEX. To gain further insights
into the regulation of the autophagy pathway, mRNA levels of
Bnip3 were measured. Both W and insulin counteracted the
increase caused by DEX treatment on Bnip3 levels (Supplemental
Fig. 2).
4. Discussion
One of the hallmarks of W is its capacity to increase ERK phos-
phorylation in several cell lines [13–17]. This enhanced activation
has been considered responsible for the increase in glucose trans-
port in skeletal muscle cells in culture [15] and for changes in gly-
cogen content observed in primary cultured rat hepatocytes [14].
In the current study, we report for the ﬁrst time that the activation
of ERK byW in skeletal muscle is capable of increasing protein syn-
thesis by activating MTOR and of decreasing protein degradation
by blocking the activity of FoxO3a. ERK activation improves protein
turnover in DEX-treated skeletal muscle cells.
Many studies have shown that MTOR plays a critical role in reg-
ulating the rate of protein synthesis and subsequent hypertrophy
in skeletal muscle [26–29]. The most well-deﬁned regulatory
mechanism of MTOR activity in skeletal muscle is the insulin/
IGF-1-dependent pathway. The administration of exogenous IGF-
1 to cultured myotubes [26] results in an increase in muscle cell
size and total protein content. However, in mice in which IGF-1
signaling is blocked by overexpression of a dominant-negative
IGF-1 receptor, skeletal muscle hypertrophies to the same degree
as in wild-type mice in response to mechanical overload [27,28].
In fact, Miyazaki et al. [27] reported that MEK/ERK signaling con-
tributes to the activation of MTOR during early response to a
mechanical overload.
Our work conﬁrms these results. W increased protein synthesis
in a dose-dependent manner. The positive effect of this compound
was caused by the phosphorylation of MTOR through an ERK-TSC2-
dependent mechanism. Moreover, the increase in protein synthesis
detected after ERK activation was similar to that obtained by Akt
activation. Also, downstream targets of MTOR, namely S6k1, 4E-
BP1 and eIF4E, were also phosphorylated either by W or insulin.
Therefore, here we have demonstrated that the activation of
ERK in rat myotubes produces a similar effect as that of Akt phos-
phorylation on protein synthesis and on the molecular mechanism
underlying this process.
Many pathological conditions characterized by muscle atrophy
(sepsis, cachexia, starvation, metabolic acidosis, severe insulope-
nia, etc.) are associated with increased circulating glucocorticoid
(GC) levels [4]. In these conditions, the rapid loss of muscle mass
occurs mainly through protein breakdown [9]. A set of atrophy
genes or atrogens that are up- or down-regulated similarly in mus-
cles in diverse types of atrophy have been identiﬁed [29,30]. These
observations indicate that common transcriptional adaptations
occur in various types of atrophy, leading to accelerated protein
degradation. In skeletal muscle, GCs decrease the rate of protein
synthesis and increase that of protein breakdown, both contribut-
ing to atrophy [31].
The stimulatory effects of GCs on muscle proteolysis result from
the activation of the major proteolytic systems: ubiquitin–protea-
some and lysosomal (autophagy). To activate protein degradation,
GCs stimulate the expression of several components of the ubiqui-
tin–proteasome pathway such as ubiquitin, ATROGEN1 and MuRF-
1 [32]. This activation of gene transcription is associated both with
increased rates of protein ubiquitination and protein degradation
C 0.5 mM W 50 nM I 
0
25
50
75
100
125
150
175
- DEX
+ DEX
U
bi
qu
iti
n 
pr
om
ot
er
 tr
an
sc
rip
tio
na
l
 a
ct
iv
ity
 (R
LU
 %
)
A * 
# # 
E
* 
# # 
C 0.5 mM W 50 nM I 
0.0
0.5
1.0
1.5
2.0
-DEX
+DEX
A
tr
og
en
1 
m
R
N
A
R
el
at
iv
e 
ex
pr
es
si
on
C * 
# 
# 
C 0.5 mM W 50 nM I 
0
1
2
3
-DEX
+DEX
M
ur
f1
 m
R
N
A
R
el
at
iv
e 
ex
pr
es
si
on
Murf1
Actin
0
50
100
150
200
-DEX
DEX
M
ur
f1
/a
ct
in
re
la
tiv
e 
in
te
ns
ity
 (%
) B * 
# 
# 
C          0.5 mM W       50nM I
0
50
100
150
200
-DEX
DEX
A
tr
og
en
1/
ac
tin
re
la
tiv
e 
in
te
ns
ity
 (%
)
Atrogen1
Actin
D * 
# 
# 
C           0.5 mM W     50nM I 
Fig. 5. Tungstate decreased UbC transcriptional activity and the expression of MuRF1 and Atrogen1 in DEX-treated myotubes. Cells were pre-incubated for 48 h in DMEM
containing 10% FBS with 0.5 mMW or 50 nM insulin and then incubated for 24 h with 5 lMDEX in the presence or absence of effectors. (A) Cells were transiently transfected
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2252 R. Salto et al. / FEBS Letters 588 (2014) 2246–2254[2,4]. The role of the lysosomal system, also called autophagy, in
the atrophic effect of GCs is proposed to occur via the increased
conversion of LC3-I to LC3-II, the latter an indicator of autophagy
[8,9,11,23].
Pioneering studies demonstrated that muscle atrophy is a result
of active processes that are transcriptionally controlled through
the expression of FoxO transcription factors [8–11,22]. The phos-
phorylation of FoxO by Akt leads to their inactivation in the cyto-
sol; however, the inhibition of the PI3K/Akt signaling pathway by
GCs triggers the dephosphorylation of FoxO and its import to the
nucleus. Several genes, such as ATROGEN1 or MuRF1, controlled
by the FoxO transcription factors, are among the genes moststrongly induced in microarray analyses of muscle atrophy caused
by a variety of wasting diseases [29,30]. Taken together, these data
indicate that increased expression of FoxO induced by GCs acti-
vates a gene transcription program responsible for triggering mus-
cle atrophy.
In the present study, we used L6 myotubes incubated with DEX
as a cellular model of protein degradation [33,34]. As expected,
DEX decreased protein synthesis and increased protein degrada-
tion, thus validating our model. Moreover, treatment of myotubes
with DEX for 24 h resulted in the activation of FoxO3a. The activity
of this transcription factor was monitored with a FoxO luciferase
reported gene and by conﬁrming its dephosphorylation in cytosolic
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R. Salto et al. / FEBS Letters 588 (2014) 2246–2254 2253samples and its increased expression in nuclear extracts. Also, the
increased FoxO activity correlated with a higher transcriptional
activity dependent on the ubiquitin promoter and increased mRNA
and protein levels of ATROGEN1 and MuRF1. Therefore, these
results suggest that the expression of ubiquitin ligases is subjected
to transcriptional control mediated by the FoxO translocation to
the nucleus.
Most attempts to prevent GC-induced muscle atrophy have
used IGF-1 or an anabolic compound that stimulates its expression
[4,12]. Studies in myoblast cell lines such as L6E9, C2C12, and L6A1
suggest that the stimulatory effect of Insulin Growth Factor I (IGF-
I) on cell proliferation and protein synthesis is mediated by theMEK/ERK and PI3K/Akt pathways; however, it is accepted that
the inhibitory effect of IGF-I on protein degradation is mediated
solely by the latter [3,12,27].
Here we show that W, an activator of the MEK/ERK but not the
PI3K/Akt pathway, prevents the deleterious effects of DEX on pro-
tein degradation. In fact, cells pre-treated with W showed a
decrease in FoxO3a activity, an increase in the phosphorylated
form in the cytosol, and a decrease in its nuclear expression when
incubated with DEX. These effects of W translated into lower ubiq-
uitin-dependent activity and a reduction of ATROGEN1 and MuRF1
mRNA levels and expression to control levels. W did not produce
changes in the activity of FoxO3a or in the expression of its molec-
ular targets. It has been reported that activation of ERK1/2 leads to
an increase in the expression of ubiquitin [34], but no such change
was observed in our study.
Our ﬁndings also show that W has the capacity to reduce the
formation of autophagosomes and the expression of the lipidated
form of LC3 in DEX-treated cells. Furthermore, W decreases the
degradation of p62, one of the speciﬁc substrates degraded through
the lysosomal pathway [23,25] and reduces the mRNA levels of
Bnip3, an autophagy-related gene whose expression is under the
control of FoxO3a [2,11], to control levels. These observations point
to the involvement of autophagy as an additional mechanism in
the W-mediated prevention of protein degradation.
In conclusion, the sole activation of MEK/ERK by W prevented
the decrease in protein synthesis and the increase in protein deg-
radation induced by DEX in our cell system. On the basis of our
results, we propose that W be considered an alternative to IGF-I
and its analogs in the prevention of skeletal muscle atrophy.5. Funding
This work was supported a Grant from the Fundación Botín to
R. Salto and Grant No. BFU2008–00769 from the Ministerio de
Ciencia e Innovacion Spain to J.J. Guinovart.
Acknowledgement
The authors thank T. Yates (IRB Barcelona) for correcting the
English manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.febslet.2014.
05.004.
References
[1] Weigl, L.G. (2012) Lost in translation: regulation of skeletal muscle protein
synthesis. Curr. Opin. Pharmacol. 12, 377–382.
[2] Shimizu, N., Yoshikawa, N., Ito, N., Maruyama, T., Suzuki, Y., Takeda, S.-I.,
Nakae, J., Tagata, Y., Nishitani, S., Takehana, K., Sano, M., Fukuda, K., Suematsu,
M., Morimoto, C. and Tanaka, H. (2011) Crosstalk between glucocorticoid
receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 13, 170–
182.
[3] Winter, J.N., Jefferson, L.S. and Kimball, S.R. (2011) ERK and Akt signaling
pathways function through parallel mechanisms to promote mTORC1
signaling. Am. J. Physiol. Cell Physiol. 300, C1172–C1180.
[4] Schakman, O., Kalista, S., Barbé, C., Loumaye, A. and Thissen, J.P. (2013)
Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. 45,
2163–2172.
[5] Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K.-L. (2002) TSC2 is phosphorylated
and inhibited by Akt and suppresses mTOR signalling. Nat. Cell. Biol. 4, 648–
657.
[6] Ma, L., Teruya-Feldstein, J., Bonner, P., Bernardi, R., Franz, D.N., Witte, D.,
Cordon-Cardo, C. and Pandolﬁ, P.P. (2007) Identiﬁcation of S664
TSC2Phosphorylation as a Marker for extracellular signal-regulated kinase–
Mediated mTOR activation in tuberous sclerosis and human cancer. Cancer
Res. 67, 7106–7112.
2254 R. Salto et al. / FEBS Letters 588 (2014) 2246–2254[7] Orlova, K.A. and Crino, P.B. (2010) The tuberous sclerosis complex. Ann. N. Y.
Acad. Sci. 1184, 87–105.
[8] Sandri, M. (2013) Protein breakdown in muscle wasting: role of autophagy–
lysosome and ubiquitin–proteasome. Int. J. Biochem. Cell Biol. 45, 2121–2129.
[9] Zhao, J., Brault, J.J., Schild, A., Cao, P., Sandri, M., Schiafﬁno, S., Lecker, S.H. and
Goldberg, A.L. (2007) FoxO3 coordinately activates protein degradation by
theautophagic/lysosomal and proteasomal pathways in atrophying muscle
cells. Cell Metab. 6, 472–483.
[10] Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo, P.,
Burden, S.J., Di Lisi, R., Sandri, C., Zhao, J., Goldberg, A.L., Schiafﬁno, S. and
Sandri, M. (2007) FoxO3 controls autophagy in skeletal muscle in vivo. Cell
Metab. 6, 458–471.
[11] Sanchez, A.M.J., Candau, R.B. and Bernardi, H. (2014) FoxO transcription
factors: their roles in the maintenance of skeletal muscle homeostasis. Cell.
Mol. Life Sci. 71, 1657–1671.
[12] Ge, X., Zhang, Y. and Jiang, H. (2013) Signaling pathways mediating the effects
of insulin-like growth factor-I in bovine muscle satellite cells. Mol. Cell.
Endocrinol. 372, 23–29.
[13] Ballester, J., Dominguez, J., Muñoz, M.C., Sensat, M., Rigau, T., Guinovart, J.J.
and Rodríguez-Gil, J.E. (2005) Tungstate treatment improves Leydig cell
function in streptozotocin-diabetic rats. J. Androl. 26, 706–715.
[14] Domínguez, J.E., Muñoz, M.C., Zafra, D., Sanchez-Perez, I., Baqué, S., Caron, M.,
Mercurio, C., Barberà, A., Perona, R., Gomis, R. and Guinovart, J.J. (2003) The
antidiabetic agent sodium tungstate activates glycogen synthesis through an
insulin receptor-independent pathway. J. Biol. Chem. 278, 42785–42794.
[15] Giron, M.D., Sevillano, N., Vargas, A.M., Dominguez, J., Guinovart, J.J. and
Salto, R. (2008) The glucose-lowering agent sodium tungstate increases
the levels and translocation of GLUT4 in L6 myotubes through a
mechanism associated withERK1/2 and MEF2D. Diabetologia 51, 1285–
1295.
[16] Nocito, L., Zafra, D., Calbó, J., Domínguez, J. and Guinovart, J.J. (2012) Tungstate
reduces the expression of gluconeogenic enzymes in STZ rats. PLoS ONE 7,
e42305.
[17] Zafra, D., Nocito, L., Domínguez, J. and Guinovart, J.J. (2013) Sodium tungstate
activates glycogen synthesis through a non-canonical mechanism involving G-
proteins. FEBS Lett. 587, 291–296.
[18] Gulve, E.A. and Dice, J.F. (1989) Regulation of protein synthesis and
degradation in L8 myotubes. Effects of serum, insulin and insulin-like
growth factors. Biochem. J. 260, 377–387.
[19] Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H.,
Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J. and Klenk, D.C.
(1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150,
76–85.
[20] Marinovic, A.C., Mitch, W.E. and Price, S.R. (2000) Tools for evaluating
ubiquitin (UbC) gene expression: characterization of the rat UbC promoterand use of an unique 3’ mRNA sequence. Biochem. Biophys. Res. Commun.
274, 537–541.
[21] Young, S.-H., Ye, J., Frazer, D.G., Shi, X. and Castranova, V. (2001) Molecular
mechanism of tumor necrosis factor-a production in 133-p-Glucan
(Zymosan)-activated Macrophages. J. Biol. Chem. 276, 20781–20787.
[22] Cho, J.E., Fournier, M., Da, X. and Lewis, M.I. (2010) Time course expression of
FoxO transcription factors in skeletal muscle following corticosteroid
administration. J. App. Physiol. 108, 137–145.
[23] Mizushima, N., Yoshimori, T. and Levine, B. (2010) Methods in mammalian
autophagy research. Cell 140, 313–326.
[24] Ohsumi, Y. (2001) Molecular dissection of autophagy: two ubiquitin-like
systems. Nat. Rev. Mol. Cell Biol. 2, 211–216.
[25] Komatsu, M. and Ichimura, Y. (2010) Physiological signiﬁcance of selective
degradation of p62 by autophagy. FEBS Lett. 584, 1374–1378.
[26] Vyas, D.R., Spangenbourg, E.E., Abraha, T.W., Childs, T.E. and Booth, F.W.
(2002) GSK-3P negatively regulates skeletal myotube hypertrophy. Am. J.
Physiol. Cell Physiol. 283, C545–C551.
[27] Miyazaki, M., McCarthy, J.J., Fedele, M.J. and Esser, K.A. (2011) Early activation
of mTORC1 signaling in response to mechanical overload is independent of
phosphoinositide 3-kinase/Akt signaling. J. Physiol. 589, 1831–1846.
[28] Spangenburg, E.E. (2009) Changes in muscle mass with mechanical load:
possible cellular mechanisms. Appl. Physiol. Nutr. Metab. 34, 328–335.
[29] Komamura, K., Shirotani-Ikejima, H., Tatsumi, R., Tsujita-Kuroda, Y., Kitakaze,
M., Miyatake, K., Sunagawa, K. and Miyata, T. (2003) Differential gene
expression in the rat skeletal and heart muscle in glucocorticoid-induced
myopathy: analysis by microarray. Cardiovasc. Drugs Ther. 17, 303–310.
[30] Lecker, S.H., Jagoe, R.T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S.R.,
Mitch, W.E. and Golberg, A.L. (2004) Multiple types of skeletal muscle atrophy
involve a common program of changes in gene expression. FASEB J. 18, 39–51.
[31] Löfberg, E., Gutierrez, A., Wernerman, J., Anderstam, B., Mitch, W.E., Price, S.R.,
Bergström, J. and Alvestrand, A. (2002) Effects of high doses of glucocorticoids
on free amino acids, ribosomes and protein turnover in human muscle. Eur. J.
Clin. Invest. 32, 345–353.
[32] Bodine, S.C., Latres, E., Baumhueter, S., Lai, V.K., Nunez, L., Clarke, B.A.,
Poueymirou, W.T., Panaro, F.J., Na, E., Dharmarajan, K., Pan, Z.Q., Valenzuela,
D.M., DeChiara, T.M., Stitt, T.N., Yancopoulos, G.D. and Glass, D.J. (2001)
Identiﬁcation of ubiquitin ligases required for skeletal muscle atrophy. Science
294, 1704–1708.
[33] Hong, D.H. and Forsberg, N.E. (1995) Effects of dexamethasone on protein
degradation and protease gene expression in rat L8 myotube cultures. Mol.
Cell. Endocrinol. 108, 199–209.
[34] Zheng, B., Ohkawa, S., Li, H., Roberts-Wilson, T.K. and Price, S.R. (2010) FoxO3a
mediated signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx
expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J.
24, 2660–2669.
